Filing Flows

Filing Flows › Allogene Therapeutics (ALLO) › Next earnings date

Allogene Therapeutics (ALLO) earnings: missed the estimate

Allogene Therapeutics (ALLO) reported on Nov 5, 2026 and missed the EPS estimate: −$0.15 against −$0.14 (-6.5%). It beat the EPS estimate in 60% of the quarters on record.

Last result−6.5% vs estimate
Beat rate60%

The last report

Allogene Therapeutics reported revenue of $4.6M for the second quarter 2026, net loss $42.7M. How it makes money → · Every quarter →

Allogene Therapeutics: EPS against the estimate, last 5 reportsAllogene Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.23−$0.19Nov 25−$0.22−$0.17Mar 26−$0.18−$0.18May 26−$0.15−$0.13Aug 26−$0.14−$0.15Nov 26
Latest (Nov 26): Estimate −$0.14, Reported −$0.15.

Allogene Therapeutics' latest quarter

Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Allogene Therapeutics beat earnings?

Allogene Therapeutics (ALLO) reported on Nov 5, 2026 and missed the EPS estimate: −$0.15 against −$0.14 (-6.5%).

When does ALLO report earnings?

The next date is not set yet.

Does Allogene Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.